Nova discovery awarded Eur 2.4M by BPI FRANCE to leverage Jinko, its clinical trial simulation platform

Debiopharm’s investment portfolio company NOVA, will conduct in silico clinical trials utilising its innovative Jinkō® platform. The results will be used to support future regulatory approval applications by ElsaLys for inolimomab in Europe.

Access the full press release here.